CytoAgents Inc. completed the dose-limiting toxicity observation for the first cohort in a trial targeting CRS in blood cancer patients. The Safety Review Committee approved dose escalation for the ...
The way late-onset toxicities are managed can affect trial outcomes and participant safety. Specifically, participants often might not have completed their entire follow-up period to observe any ...
PITTSBURGH--(BUSINESS WIRE)--CytoAgents Inc., a clinical-stage biotechnology company developing CTO1681 for the prevention and treatment for Cytokine Release Syndrome (CRS), announced the successful ...
SOUTH SAN FRANSCISCO, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo” or the “Company”), an immunotherapy company developing the next generation of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback